Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) shares reached a new 52-week low on Monday . The stock traded as low as C$3.76 and last traded at C$4.01, with a volume of 3775 shares changing hands. The stock had previously closed at C$4.05.

Separately, TD Securities reduced their target price on shares of Cipher Pharmaceuticals from C$6.50 to C$5.00 and set a “hold” rating for the company in a report on Tuesday, November 7th.

The stock has a market cap of $107.69, a PE ratio of -19.29 and a beta of 1.26.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings results on Friday, November 3rd. The company reported C$0.22 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of C$0.18 by C$0.04. Cipher Pharmaceuticals had a net margin of 44.75% and a return on equity of 113.74%.

In other news, Director Harold Morton Wolkin purchased 35,000 shares of the company’s stock in a transaction on Friday, November 10th. The shares were purchased at an average cost of C$4.69 per share, with a total value of C$164,150.00.

WARNING: “Cipher Pharmaceuticals (CPH) Reaches New 1-Year Low at $3.76” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with's FREE daily email newsletter.